Furthermore, different studies have shown albumin-based nanoparticles involved in anticancer therapies in clinical trials; one example is the nanocomposite Abraxane, adopted as therapeutic agent for pancreatic cancer, non-small cell lung cancer, and breast cancer. This evidence concerns the gene ALB and non-small cell lung carcinoma.